Publications


Utilization of (134)Cs/(137)Cs in the environment to identify the reactor units that caused atmospheric releases during the Fukushima Daiichi accident.
Sci Rep 2016 Aug 22;6:31376. Epub 2016 Aug 22.
Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 45-169 Harama-chiku Kaibama sukakeba, Minamisoma City, Fukushima 975-0036, Japan.


The air dose rate around the Fukushima Dai-ichi Nuclear Power Plant: its spatial characteristics and temporal changes until December 2012.
J Environ Radioact 2015 Jan 20;139:250-9. Epub 2014 Sep 20.
Fukushima Environmental Safety Center, Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 2-2-2, Uchisaiwai-cho, Chiyoda, Tokyo 100-8577, Japan. Electronic address:

Spatial distributions of radionuclides deposited onto ground soil around the Fukushima Dai-ichi Nuclear Power Plant and their temporal change until December 2012.
J Environ Radioact 2015 Jan 11;139:320-43. Epub 2014 Oct 11.
Fukushima Environmental Safety Center, Sector of Fukushima Research and Development, Japan Atomic Energy Agency, 2-2-2, Uchisaiwai-cho, Chiyoda, Tokyo, 100-8577, Japan. Electronic address:

A translation system reconstituted with human factors proves that processing of encephalomyocarditis virus proteins 2A and 2B occurs in the elongation phase of translation without eukaryotic release factors.
J Biol Chem 2014 Nov 25;289(46):31960-71. Epub 2014 Sep 25.
From the Department of Materials Science and Chemistry and Molecular Nanotechnology Research Center, Graduate School of Engineering, University of Hyogo, Himeji 671-2201, Japan and

Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis.
J Bone Miner Metab 2014 May 6;32(3):271-80. Epub 2013 Jul 6.
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.






Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
ACS Med Chem Lett 2010 Sep 18;1(6):290-4. Epub 2010 Jun 18.
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd., 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan.

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
Bone 2009 Nov 23;45(5):949-55. Epub 2009 Jul 23.
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, B6, 2-2 Yamadaoka, Suita, Osaka, Japan.

Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Bone 2009 Apr 9;44(4):678-83. Epub 2008 Dec 9.
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Box B6, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.


Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Nephrol Dial Transplant 2007 Jun 23;22(6):1601-7. Epub 2006 Nov 23.
FASN Department of Internal Medicine, Osaka University School of Medicine, Box A8, 2-2 Yamada-oka, Suita 565-0871, Japan.

OF